- 2026 IPO stock tracker: How newly public biotechs are performingBioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.BioSpace · 2d ago↗ source
- Novartis scraps mid-stage radiopharma asset as Pluvicto soarsThe discontinued asset, being trialed for breast cancer and solid tumors, had yielded disappointing data, leading to Novartis’ decision to abandon development, according to a company spokesperson.BioSpace · 2d ago↗ source
- Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics spa…